Sign in

    Jacob Seed

    Research Analyst at TD Cowen

    Jacob Seed is an equity research analyst at TD Cowen in New York, specializing in healthcare sector coverage with a focus on major pharmaceutical and biotechnology companies. Noted for contributing investment recommendations as part of the healthcare team, Seed has participated in deal processes and research activities that have helped inform buy- and sell-side investment decisions, although specific performance or ranking metrics are not publicly available. He began his finance career after completing academic training, gaining entry to TD Cowen via competitive recruiting programs, and has participated in investment research since at least late 2023. Seed holds industry-relevant certifications and has completed rigorous technical evaluations, equipping him with a robust foundation in financial modeling and sector analysis.

    Jacob Seed's questions to DESP leadership

    Jacob Seed's questions to DESP leadership • Q2 2024

    Question

    Asked for the specific revenue and EBITDA contribution from the divested DMC business and questioned how much of the raised EBITDA guidance was attributable to the associated employee transition versus other cost savings.

    Answer

    Due to a confidentiality agreement, the company could not provide exact financial figures for the DMC divestiture but noted it involved 600 of 4,600 employees and had slightly lower margins than the company average. The raised EBITDA guidance is primarily a result of broad operational efficiencies being driven across the entire business, not a significant impact from the employee transition related to the divestment.

    Ask Fintool Equity Research AI